|
Market Closed -
Nasdaq
02:30:00 03/12/2025 am IST
|
5-day change | 1st Jan Change | ||
| 1.260 USD | -59.35% |
|
-.--% | - |
| 17/12 | Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 | CI |
| 03/12 | Top Midday Decliners | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||
Pharmaceuticals | 5L | 3L | 1L | 18.63T | 10L | |||
Total Assets | 2.9Cr | 58.3L | 54.29L | 27.71L | 1.49Cr | |||
Interest Expense | - | - | - | - | -6L | |||
Income Tax Expense | - | - | - | - | 2L | |||
CAPEX | -3.62T | - | - | - | - | |||
EBT | -2.5Cr | -2.97Cr | -1.88Cr | -74.37L | -1.58Cr | |||
D&A | 95.16T | 93.26T | 75.75T | 83.12T | 89.26T | |||
Operating Income | -2.51Cr | -2.97Cr | -1.88Cr | -1.18Cr | -1.58Cr | |||
Net Income | -2.5Cr | -2.97Cr | -1.88Cr | -74.37L | -1.6Cr |
| Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
United States | 5L | 3L | 1L | 18.63T | 10L | |||
Total Assets | 2.9Cr | 58.3L | 54.29L | 27.71L | 1.49Cr | |||
Interest Expense | - | - | - | - | -6L | |||
Income Tax Expense | - | - | - | - | 2L | |||
D&A | 95.16T | 93.26T | 75.75T | 83.12T | 89.26T | |||
CAPEX | -3.62T | - | - | - | - | |||
Net Income | -2.5Cr | -2.97Cr | -1.88Cr | -74.37L | -1.6Cr | |||
EBT | -2.5Cr | -2.97Cr | -1.88Cr | -74.37L | -1.58Cr | |||
Operating Income | -2.51Cr | -2.97Cr | -1.88Cr | -1.18Cr | -1.58Cr |
- Stock Market
- Stocks
- SONN Stock
- Financials Sonnet Biotherapeutics
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
